Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271291 · ClinicalTrials.gov registry record
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
A clinical trial of Pancreatic Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 30,000
- Enrollment target
- 7
- Study locations
NCT06271291: Recruiting study of Pancreatic Carcinoma, sponsored by Mayo Clinic.
NCT06271291 is a study of Pancreatic Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30,000 participants, above the 1,818-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (1550% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06271291, a study of Pancreatic Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 30,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.
Primary Outcome
Assessed by the number of specimens collected for subjects at right risk for pancreatic cancer due to a strong family history, a mutation in a known pancreatic cancer predisposition gene, or Fukuoka worrisome or high-risk pancreatic cysts.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (7)
Arizona
- HonorHealth Research Institute - Scottsdale
Georgia
- Piedmont Healthcare - Atlanta
Illinois
- OSF Saint Francis Medical Center - Peoria
Minnesota
- Mayo Clinic in Rochester - Rochester
Nebraska
- University of Nebraska Medical Center - Omaha
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2029-11-01 |
What NCT06271291 shows while recruiting
NCT06271291 is an observational study that tracks outcomes without assigning an intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,818-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (1550% higher).
The record links to 1 condition, with Pancreatic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06271291 lists 7 locations in 7 states (Arizona, Georgia, Illinois).
Frequently Asked Questions
What is clinical trial NCT06271291 about?
NCT06271291 is a clinical study titled "Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts". This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.
What is the current status of trial NCT06271291?
This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2024-12-12. Estimated completion is 2029-11-01.
What conditions does trial NCT06271291 study?
This clinical trial studies the following conditions: Pancreatic Carcinoma.
What interventions are being tested in trial NCT06271291?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06271291?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06271291 being conducted?
This trial has 7 study locations across Arizona, Georgia, Illinois, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06271291's enrollment target sits among peer trials
30,000 1st of 18 higher than 18 of 18 other Pancreatic Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
RECRUITING · Phase 3
-
Pilot Study of Pancreatic Cancer Screening
RECRUITING
-
Use Of Indocyanine Green In Pancreas Surgery
RECRUITING
-
A Study of MGC028 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Pancreatic Cancer Detection Consortium
RECRUITING
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI